Citations

Mayo Clinic

Showing 10 of 108522 citations.

In Response
Blike, George T. , McGrath, Susan P. , Kinney, Michelle A. O. , Gali, Bhargavi , Ochs Kinney, Michelle A

Anesthesia & Analgesia | August 22, 2024 | Volume: 139 | Issue: 5 | Pages: e53-e53

10.1213/ane.0000000000007197 | PMID 39167542 Get It

Survey of Hematology/Oncology Program Leaders on Equity and Global Health Opportunities for Fellows
Falade, Ayo , Hornstein, Paula, Slater, Sarah, Triedman, Scott A. , Buswell, Lori , Fadelu, Temidayo , Falade, Ayo S , Buswell, Lori A , Fadelu, Temidayo A , Slater, Sarah E.

JCO Global Oncology | August 22, 2024 | Volume: No volume available | Issue: 10 | Pages: No page available

10.1200/go-24-00254 | PMID 39173079 Get It

PURPOSE The study assesses the current state of global oncology (GO)/hematology training opportunities in US fellowship programs. METHODS We developed a comprehensive survey of 64-Likert multiple-choice and open-ended questions. The survey was electronically distributed to fellowship program leaders at Accreditation Council for Graduate Medical Education-accredited adult hematology/oncology fellowships. Program directors received three reminders after which survey was sent to assistant program directors or division heads for programs not represented. RESULTS A total of 171 programs were eligible for the survey. We received 42 (24.6%) responses; 40 were included in the analysis, and two were excluded for declined consent and incomplete responses. The programs include large academic (81.6%) and community hospitals (10.5%). Of the respondents, 18 (48.6%) reported offering some opportunities for global health training, and half reported interest among current fellows. Most programs (29, 82.9%) had three or fewer faculty engaged in GO research. Institutional training grants were available in 15 (39.5%) programs, of which six (40%) allowed for global health research. Of the 18 programs offering global health training activities, most (15, 83.3%) report less than a quarter of their trainees currently participate in GO experiences. The most commonly perceived barriers to GO opportunities include competing priorities (85.3%) and lack of faculty mentors with GO-related experience (82.4%). Conversely, the most commonly perceived facilitators include established partnerships outside the United States (97.0%) and dedicated institutional funding (93.9%). CONCLUSION Our survey demonstrates that although there is significant interest among fellowship trainees, a minority of the fellowship programs offer GO opportunities. Providing GO opportunities would require programs to establish partnerships with institutions outside the United States and to have systematic approaches of addressing other barriers, including enhancing funding and mentorship.
Velopharyngeal Gap Size During Sustained Vowel Production Correlates With Perceptual Ratings of Hypernasality in Connected Speech
Chee-Williams, Jessica L. , Perry, Jamie L. , Bunton, Kate , Cordero, Kelly Nett , Snodgrass, Taylor D. , Singh, Davinder , Temkit, Hamy, Sitzman, Thomas J. , Singh, Davinder J , Sitzman, Thomas J , Chee-Williams, Jessica L , Cordero, Kelly N , Snodgrass, Taylor , Perry, Jamie L

Journal of Speech, Language, and Hearing Research | August 22, 2024 | Volume: 67 | Issue: 9 | Pages: 2977-2986

10.1044/2024_jslhr-24-00221 | PMID 39173051 Get It

Purpose: The purpose of this study was to investigate the relationship between perceptual ratings of hypernasality made during connected speech and velopharyngeal (VP) gap size measured in millimeters in the sagittal plane during sustained vowel production using magnetic resonance imaging (MRI). Method: A retrospective cross-sectional analysis was completed. A subgroup of 110 participants from another study with an M age of 10.1 years presenting for management of VP insufficiency was included. Perceptual ratings of hypernasality during connected speech and measurement of gap size during sustained /i/ production on MRI were performed by raters blinded to the participants' medical and surgical history. Results: There was a moderate-to-strong, positive correlation ( r = .61; p < .001) between hypernasality ratings and VP gap size measured on MRI using sustained /i/. The odds of a higher hypernasality rating increased as the gap size increased (odds ratio = 1.34; 95% CI [1.20, 1.49]; p < .001). The predicted probability for hypernasality ratings of none/minimal/mild steadily decreased as the gap size increased indicating that lower ratings of hypernasality were associated with smaller gap sizes. For the rating of “moderate” hypernasality, the predicted probability of the rating steadily increased up to 8 mm and then decreased as the gap size continued to increase. The predicted probability for a hypernasality rating of “severe” consistently increased as the gap size increased. Conclusions: Hypernasality ratings made at the connected speech level were significantly associated with VP gap size as measured during sustained vowel production. These findings suggest sustained vowel production elicited on MRI may adequately characterize VP gap size in the evaluation of VP insufficiency.
Fecal Microbiota Transplantation (FMT) and Clinical Outcomes among Inflammatory Bowel Disease (IBD) Patients: An Umbrella Review
Malik, Sheza , Arsalan, Syed Shakeeb , Shadali, Abul Hasan, Khan, Hajra, Christof, Michael , Niu, Chengu , Adler, Douglas G., Naqvi, Syed Arsalan Ahmed , Khan, Hajra, Schwartz, David A.

No container title available | August 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4758866/v1 Get It

Abstract Background and Aims: Recent systematic reviews and meta-analyses (SRMAs) have shown inconsistent effectiveness of FMT among IBD patients. This study aimed to appraise the evidence for clinically relevant outcomes with FMT in IBD patients using published SRMAs. Methods: We searched major databases from inception through Nov 2023 to identify SRMAs assessing the effectiveness of FMT in IBD patients. Primary outcomes included clinical remission, clinical response, endoscopic remission/response, a composite endpoint, and adverse effects. We included SRMAs investigating FMT's effect in IBD patients using RCTs and observational studies data. Methodological quality and evidence certainty were assessed using AMSTAR 2 and GRADE. Results: Out of 106 citations, 16 SRMAs were included with varying study sizes (2 to 60 primary studies) and participants (112 to 1169 per SRMA). Five SRMAs assessed FMT in IBD, while 11 focused on Ulcerative Colitis (UC). Seven SRMAs included RCTs only, and nine included both RCTs and observational studies. Methodological quality was critically low in 9 SRMAs (56%) and low in 7 studies (44%). FMT showed clinical remission benefit in all 16 SRMAs, with varying certainty: 3 high, 4 moderate, 4 low, and 5 very low. Endoscopic remission/response was reported in 5 meta-analyses on UC, with 1 high, 3 moderate, and 1 very low certainty. Combined clinical remission and endoscopic response were reported in 3 SRMAs on UC, with 1 low and 2 moderate certainty. Adverse events were reported in 6 SRMAs, with 1 high, 3 moderate, 1 low, and 1 very low certainty. Conclusion: Current evidence shows potential benefits of FMT in IBD, particularly UC, supported by significant associations in 16 meta-analyses. However, poor methodological quality and variability in evidence certainty call for high-quality RCTs to strengthen the evidence.
Difference in precocious puberty between pre–COVID-19 and COVID-19 periods: a meta-analysis
Nguyen, Nam Nhat , Dang, Tri Do, Hieu, Truong Hong , Nam, Anh , Cheng, Yang-Ching, Truong, Hieu Hong , Chen, Yang-Ching

American Journal of Epidemiology | August 22, 2024 | Volume: 194 | Issue: 4 | Pages: 1131-1139

10.1093/aje/kwae295 | PMID 39168833 Get It

Abstract We conducted this systematic review and meta-analysis to clarify the trend of precocious puberty (PP) incidence after the COVID-19 outbreak and explore potential contributing factors, such as age at presentation and body mass index (BMI) SD score (SDS). Children visiting pediatric endocrinology clinics for the first time for suspected PP were included. We searched databases until February 28, 2023, for studies reporting various indicators of PP incidence before and during the pandemic. Total numbers of events and observations were recorded. A meta-analysis was performed to compare the odds of PP, BMI SDS, and age at presentation between the 2 periods. The dose-response relationships between time points (by number of years away from the pandemic) and PP risk were explored. In summary, a total of 32 studies including 24 200 participants were recruited. The COVID-19 pandemic was associated with the increasing odds of PP among children referred for a suspicious condition (odds ratio = 1.96; 95% CI, 1.56-2.47; I2 = 54%; P &lt; .001). Sensitivity analysis confirmed the robustness of the findings. The BMI SDS did not vary between the 2 periods, whereas age at presentation was lower after the pandemic. Precocious puberty incidence increased more rapidly during the pandemic period than during the prepandemic period. Trial registration: International Prospective Register of Systematic Reviews (PROSPERO; identifier: CRD42023402212)
Immune Checkpoint Inhibitor–Induced Cardiotoxicity
Nielsen, Ole Haagen , Herrmann, Joerg , Nielsen, Dorte Lisbet , Juhl, Carsten Bogh , Chen, Inna Markovna

JAMA Oncology | August 22, 2024 | Volume: 10 | Issue: 10 | Pages: 1390

10.1001/jamaoncol.2024.3065 | PMID 39172480 Get It

ImportanceImmune checkpoint inhibitors (ICIs) improve outcomes in a wide range of cancers; however, serious adverse effects, including cardiovascular adverse effects (CVAEs), can occur.ObjectiveTo determine the incidence of CVAEs and analyze data on the management of myocarditis in patients exposed to ICIs.Data SourcesPubMed, Embase, and Cochrane Central Register of Controlled Trials from inception were searched on April 4, 2023.Study SelectionTwo separate studies were performed. Key inclusion criteria for study 1 were phases 1 to 4 trials involving adults with malignant neoplasms treated with an ICI and toxicity data; for study 2, publications (case reports and retrospective analyses) on clinical manifestations and treatment of patients with ICI-induced CVAEs. Studies with dose escalation or fewer than 11 patients in each group and all case reports, retrospective analyses, letters, reviews, and editorials were excluded from study 1. Studies not published in English were excluded from study 2.Data Extraction and SynthesisThe PRISMA guidelines and Cochrane Handbook for Systematic Reviews were followed. Data were extracted independently by 2 researchers. A meta-analysis of the incidence of CVAEs in clinical trials and a systematic review of the evidence for the management of myocarditis were performed. Data were pooled using a random-effects model.Main Outcomes and MeasuresIn study 1, the primary outcome was incidence CVAEs in clinical trials with ICIs and ICI combination therapies. Study 2 examined evidence supporting specific management strategies that may decrease the mortality rate of myocarditis. The primary outcomes were planned before data collection began.ResultsIn study 1, a total of 83 315 unique participants in 589 unique trials were included in the meta-analysis. Incidence of CVAEs induced by anti–programmed cell death 1 and/or programmed cell death ligand 1 was 0.80% (95% CI, 0%-1.66%) in clinical trials, with no differences between the compounds, except for cemiplimab, which was associated with a higher risk of CVAEs. Incidence of CVAEs following ipilimumab treatment was 1.07% (95% CI, 0%-2.58%). The incidence of myocarditis was significantly higher following treatment with dual ICIs. However, CVAE incidence was not higher with dual ICIs, ICI combination with chemotherapy, or tyrosine kinase inhibitors. Evidence from randomized clinical trials on recommended monitoring and treatment strategies for ICI-induced myocarditis was lacking. Study 2 showed that myocarditis-associated mortality occurred in 83 of 220 patients (37.7%). Prospective data from 40 patients with myocarditis indicated that systematic screening for respiratory muscle involvement, coupled with active ventilation, prompt use of abatacept, and the addition of ruxolitinib, may decrease the mortality rate.Conclusions and RelevanceImmune checkpoint inhibitor–induced CVAEs and/or myocarditis were recorded in 1.07% of patients in clinical trials. The CVAE mortality risk remains high, justifying the need for monitoring and management strategies for which evidence from randomized clinical trials is absent. Early recognition, ICI therapy cessation, prompt initiation of corticosteroid therapy, and escalation of therapy are all crucial elements for achieving optimal outcomes. Prospective clinical trials or at least prospective registration of treatments and outcomes are highly warranted.
Conunetr: A Conditional Transformer Network for 3D Micro-Ct Embryonic Cartilage Segmentation
Sapkota, Nishchal, Perrine, Susan M. Motch , Hsi, Yuhan, Li, Sirui , Holmes, Greg , Abdulai, Abdul R., Wu, Meng, Jabs, Ethylin W , Zhang, Yejia , Wu, Meng Chao , Richtsmeier, Joan T. , Chen, Danny Z.

2024 IEEE International Symposium on Biomedical Imaging (ISBI) | August 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/isbi56570.2024.10635851 | PMID 41018045 Get It

Pre-Training Graph Attention Convolution for Brain Structural Imaging Biomarker Analysis and Its Application to Alzheimer’s Disease Pathology Identification
Yang, Zhangsihao , Farazi, Mohammad , Zhu, Wenhui , Chen, Yanxi , Reiman, Eric M. , Caselli, Richard J., Leporé, Natasha , Su, Yi , Rouhi, Rahimeh , Caselli, Richard J. , Chen, Kewei , Wang, Yalin

2024 IEEE International Symposium on Biomedical Imaging (ISBI) | August 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/isbi56570.2024.10635797 Get It

Heat and carbon monoxide exposure: Is two better than one?
Webb, Kevin L. , González‐Alonso, José , Webb, Kevin L

Experimental Physiology | August 22, 2024 | Volume: 109 | Issue: 10 | Pages: 1627-1628

10.1113/ep092198 | PMID 39173128 Get It

Multi-modal Predictive Model for MACE Risk Estimation in Patients with Migraine
Tariq, Amara , Dumitrașcu, Oana , Luo, Man , Dumkrieger, Gina , Schwedt, Todd J. , Chong, Catherine D. , Banerjee, Imon

2024 IEEE 12th International Conference on Healthcare Informatics (ICHI) | August 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: 684-687

10.1109/ichi61247.2024.00109 Get It